Abstract
Autoimmune neuromuscular disorders affecting peripheral nerves, neuromuscular junction or muscle have a wide clinical spectrum with diverse pathogenetic mechanisms. Peripheral nervous system may be targeted in the context of complex immune reactions involving different cytokines, antigen-presenting cells, B cells and different types of T cells. Various immunomodulating and cytotoxic treatments block proliferation or activation of immune cells by different mechanisms attempting to control the response of the immune system and limit target organ injury. Most treatment protocols for autoimmune neuromuscular disorders are based on the use of corticosteroids, intravenous immunoglobulins and plasmapheresis, with cytotoxic agents mostly used as steroid-sparing medications. More recently, development of specific monoclonal antibodies targeting individual cell types allowed a different approach targeting specific immune pathways, but these new treatments are also associated with various adverse effects and their long-term efficacy is still unknown.
Keywords: Autoimmune, neuromuscular, neuropathy, myositis, myasthenia gravis, treatment, pathogenetic mechanisms, corticosteroids, myelin proteins, cerebrospinal fluid (CSF), vasopressin, angiotensin, pharmacology
Current Neuropharmacology
Title: Autoimmune Neuromuscular Disorders
Volume: 9 Issue: 3
Author(s): Jessica Kraker and Sasa A. zivkovic
Affiliation:
Keywords: Autoimmune, neuromuscular, neuropathy, myositis, myasthenia gravis, treatment, pathogenetic mechanisms, corticosteroids, myelin proteins, cerebrospinal fluid (CSF), vasopressin, angiotensin, pharmacology
Abstract: Autoimmune neuromuscular disorders affecting peripheral nerves, neuromuscular junction or muscle have a wide clinical spectrum with diverse pathogenetic mechanisms. Peripheral nervous system may be targeted in the context of complex immune reactions involving different cytokines, antigen-presenting cells, B cells and different types of T cells. Various immunomodulating and cytotoxic treatments block proliferation or activation of immune cells by different mechanisms attempting to control the response of the immune system and limit target organ injury. Most treatment protocols for autoimmune neuromuscular disorders are based on the use of corticosteroids, intravenous immunoglobulins and plasmapheresis, with cytotoxic agents mostly used as steroid-sparing medications. More recently, development of specific monoclonal antibodies targeting individual cell types allowed a different approach targeting specific immune pathways, but these new treatments are also associated with various adverse effects and their long-term efficacy is still unknown.
Export Options
About this article
Cite this article as:
Kraker Jessica and A. zivkovic Sasa, Autoimmune Neuromuscular Disorders, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796558000
DOI https://dx.doi.org/10.2174/157015911796558000 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Medical Complications of Anorexia Nervosa and Their Treatments
Current Women`s Health Reviews Mechanism and Development of Modern General Anesthetics
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Strategies to Avoid TAVI-related Acute Kidney Injury
Current Pharmaceutical Design Role of the Sympathetic Nervous Activity in Hypertension-Update in 2013
Current Hypertension Reviews New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications
Letters in Drug Design & Discovery Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Analysis of Annulated Sea Snake Venom, Hydrophis Cyanocinctus, Using Liquid Chromatography and MALDI-TOF/TOF
Current Proteomics C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design <i>Scaphechinus mirabilis</i> Extract Effectively Inhibits the Proliferation of BPH-1 and LNCaP Prostate Epithelial Cells
The Natural Products Journal Dopexamine After Heart Surgery: An Uncommonly Used, Though Useful Inotropic Agent
Recent Patents on Cardiovascular Drug Discovery Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Editorial (Current Thought in Perinatal Haemodynamics)
Current Pediatric Reviews A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry